Stimuli Responsive-Nano-Drug Targeting for Cancer Treatment and Theranostics - Amjad Kamal, Mohammad; Singh, Arun Kumar; Chopra, Hitesh; Rai, Arya
162,99 €
inkl. MwSt.
Versandkostenfrei*
Erscheint vorauss. 1. Oktober 2025
payback
81 °P sammeln
  • Broschiertes Buch

Stimuli Responsive-Nano-drug Targeting for Cancer Treatment and Theranostics is a groundbreaking book that offers cutting-edge insights into the role of nanotechnology in cancer therapy. This book serves as a bridge between theoretical concepts and rigorous investigations, focusing on material carriers for chemotherapeutic drugs. It emphasizes structural features and targeted approaches that enhance therapeutic efficacy. The book comprises 18 chapters that delve into nanocarriers in cancer research, cancer therapies, and the application of Artificial Intelligence in stimuli…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Stimuli Responsive-Nano-drug Targeting for Cancer Treatment and Theranostics is a groundbreaking book that offers cutting-edge insights into the role of nanotechnology in cancer therapy. This book serves as a bridge between theoretical concepts and rigorous investigations, focusing on material carriers for chemotherapeutic drugs. It emphasizes structural features and targeted approaches that enhance therapeutic efficacy. The book comprises 18 chapters that delve into nanocarriers in cancer research, cancer therapies, and the application of Artificial Intelligence in stimuli responsive-Nano-drug targeting. Each chapter includes illustrative examples, making it a valuable resource for health professionals, scientists, researchers, practitioners, and students.
Autorenporträt
Mohammad Amjad Kamal is Distinguished Adjunct Professor at King Fahd Medical Research Center, King Abdulaziz University, Saudi Arabia. Professor Kamal's overall biochemical research output has culminated in more than 600 publications in journals of international repute and 61 abstracts in international conferences. His research was pivotal in supporting the development of the novel anti-Alzheimer agents from the laboratory to the clinic via collaboration with Dr Nigel H. Greig (United States). He migrated to Australia in 1998 and was awarded a prestigious U2000 Postdoctoral Fellowship in 2000 by the University of Sydney, School of Molecular and Microbial Biosciences.